Q4 2024 Hims & Hers Health Inc Earnings Call Transcript
Key Points
- Hims & Hers Health Inc (HIMS) reported a significant year-over-year revenue growth of 95% for the fourth quarter and 69% for the full year 2024, reaching $1.5 billion.
- The company successfully expanded its subscriber base by 45% to over 2.2 million, with over 55% subscribing to at least one personalized solution.
- Hims & Hers Health Inc (HIMS) achieved its first full year of GAAP profitability with a net income of $126 million.
- The company is investing in technology and infrastructure, including whole body lab testing and a peptide facility, to enhance personalized treatment offerings.
- Hims & Hers Health Inc (HIMS) is leveraging AI and data analytics to improve telehealth offerings and patient outcomes, with plans for AI-driven diagnostics and automation.
- Gross margins declined approximately 2 points quarter-over-quarter, primarily due to the scaling of the GLP-1 offering and strategic pricing actions.
- The company anticipates some pressure on gross and adjusted EBITDA margins in the first quarter of 2025 due to strategic pricing actions and marketing investments.
- There is a potential risk of regulatory challenges related to the personalization of GLP-1 dosages, which could impact the company's offerings.
- The transition away from commercially available semaglutide doses may lead to a loss of some subscribers seeking branded options.
- Hims & Hers Health Inc (HIMS) faces challenges in sourcing branded medications reliably, impacting the consistency and transparency of pricing for customers.
Good afternoon, ladies and gentlemen, and thank you for standing by. My name is Kelvin, and I will be your conference operator today. At this time, I would like to welcome everyone to the Hims & Hers' fourth quarter 2024 earnings call. (Operator Instructions) I would now like to turn the call over to Bill Newby, Head of Investor Relations. Please go ahead.
Good afternoon, everyone, and welcome to the Hims & Hers Health's fourth quarter and full year 2024 earnings call. Today, after the market closed, we released this quarter's shareholder letter, a copy of which you can find on our website at investors.hims.com. On the call with me today is Andrew Dudum, our Co-Founder and Chief Executive Officer; and Yemi Okupe, our Chief Financial Officer. Before I hand it over to Andrew, I need to remind you of legal safe harbor and cautionary declarations. Certain statements and projections of future results made in this presentation constitute forward-looking statements that are based on, among
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
